Establishment and characterization of a novel Philadelphia-chromosome positive chronic myeloid leukemia cell line, TCC-S, expressing P210 and P190 BCR/ABL transcripts but missing normal ABL gene

Springer Science and Business Media LLC - Tập 18 - Trang 25-33 - 2013
Phan Nguyen Van Thanh1,2, Phan Thi Xinh1,2, Yasuhiko Kano3, Katsushi Tokunaga2, Yuko Sato1
1Division of Ultrafine Structure, Department of Pathology, Research Institute, International Medical Center of Japan, Tokyo, Japan
2Department of Human Genetics, School of International Health, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan
3Division of Hematology and Medical Oncology, Tochigi Cancer Center, Tochigi, Japan

Tóm tắt

A novel Philadelphia-chromosome positive (Ph+) cell line, TCC-S, has been established from a patient with Ph+ chronic myeloid leukemia (CML) in the blastic crisis. TCC-S cells were shown to express both P210 and P190 BCR/ABL transcripts by reverse transcriptase-polymerase chain reaction (PCR), although quantitative-PCR revealed that TCC-S cells mainly expressed P210 BCR/ABL transcript. Karyotype analysis revealed several triploid clones which constantly harbored two der(9)del(9)(p12)t(9;22)(q34;q11)s and two del(9)(q21)s. The der(9)del(9)(p12)t(9;22)(q34;q11) is rarely found in other CML cell lines. Moreover, to the best of our knowledge, del(9)(q21) resulting in missing of a restrict region including normal ABL gene has not been found among CML cell lines previously described. Thus, TCC-S cells with only BCR/ABL gene and no normal ABL gene may be a useful tool for functional study of ABL in Ph+ CML.

Tài liệu tham khảo

Kantarjian HM, Deisseroth A, Kurzrock R, et al.: Chronic myelogenous leukemia. Blood. 82: 691–703, 1993. Drexler HG, Macleod RAF and Uphoff CC: Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia. Leukemia Res. 23: 207–215, 1999. Deininger MW, Goldman JM and Melo JV: The molecular biology of chronic myeloid leukemia. Blood. 96: 3343–3356, 2000. Goldman JM and Melo JV: Chronic myeloid leukemia--advances in biology and new approaches to treatment. N Engl J Med. 349: 1451–1464, 2003. Melo JV: The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood. 88: 2375–2384, 1996. Saglio G, Guerrasio A, Rosso C, et al.: New type of bcr/abl junction in Philadelphia chromosome-positive chronic myelogenous leukemia. Blood. 76: 1819–1824, 1990. Pane F, Frigeri F, Sidona M, et al.: Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with c3/a2 junction). Blood. 88: 2410–2414, 1996. Miyawaki S, Tanimoto M, Kobayashi T, et al.: Effect of etoposide added to individualized induction therapy of adult acute myeloid leukemia —the JUG —AML —92 Study Japan Adult Leukemia Study Group. Int J Hematol. 70: 87–104, 1999. Schoumans J, Nielsen K, Jeppesen I, et al.: A comparison of different metaphase CGH methods for the detection of cryptic chromosome aberrations of defined size. Eur J Hum Genet. 2004. Yanagisawa K, Yamauchi H, Kaneko M, et al.: Suppression of cell proliferation and the expression of a bcr-abl fusion gene and apoptotic cell death in a new human chronic myelogenous leukemia cell line, KT-1, by interferon-α. Blood. 91: 641–648, 1998. Beran M, Pisa P, O’Brien S, et al.: Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous leukemia cells in the blastic phase. Cancer Res. 53: 3603–3610, 1993. Rhee FV, Hochhaus A, Lin F, et al.: p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias. Blood. 87: 5213–5217, 1996. Oez S, Tittelbach H, Fahsold R, et al.: Establishment and characterization of a granulocyte-macrophage colony-stimulating factor-dependent human myeloid cell line. Blood. 76: 578–582, 1990. Okamura J, Yamada S, Ishii E, et al.: A novel leukemia cell line, MR-87, with positive Philadelphia chromosome and negative breakpoint cluster region rearrangement coexpressing myeloid and early B-cell markers. Blood. 72: 1261–1268, 1988. Kolomietz E, Al-Maghrabi J, Brennan S, et al.: Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis. Blood. 97: 3581–3588, 2001. Quintas-Cardama A, Kantajian H, Talpaz M, et al.: Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood. 105: 2281–2286, 2005.